Xeljanz XR (Tofacitinib Citrate) Patent Expiration, LOE Window & CMS Spending
Xeljanz XR (Tofacitinib Citrate) by Pfizer: FDA Orange Book core substance LOE 2026-06-08 (last listed 2034-09-14), 10 AB generics, $718.8M 2024 CMS Part D & Medicaid spend, and $5,536 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N208246 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-06-08 |
| Last Listed Patent or Exclusivity Date | 2034-09-14 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $718.8M |
| 2024 Medicare Part D Spend | $589.8M |
| 2024 Medicaid Spend | $129.0M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($5,536 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.